A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 4, 2011, Pages 491-499

  Murray, Maeve P ^a,b,c   Govan, John R W ^b   Doherty, Catherine J ^b   Simpson, A John ^c   Wilkinson, Thomas S ^c   Chalmers, James D ^c   Greening, Andrew P ^c,d   Haslett, Christopher ^c   Hill, Adam T ^a,c  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bronchiectasis; Gentamicin; Nebulized anibiotics

Indexed keywords

GENTAMICIN; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BACTERIAL LOAD; BRONCHIECTASIS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; EXERCISE; EXPIRATORY FLOW; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMAL MID EXPIRATORY FLOW; NEBULIZATION; NON CYSTIC FIBROSIS BRONCHIECTASIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPUTUM CULTURE; SPUTUM LEVEL;

ADMINISTRATION, INHALATION; AEROSOLS; AGED; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; FEMALE; FOLLOW-UP STUDIES; GENTAMICINS; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; SODIUM CHLORIDE; TREATMENT OUTCOME;

EID: 79951824943     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201005-0756OC     Document Type: Article

References (43)

1. Laennec R. A treatise in the diseases of the chest and on mediate auscultation (1819), 4th ed. London: Longman; 1834.
2. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006;100:2183-2189. (Pubitemid 44718391)
3. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005;128:739-745. (Pubitemid 41140504)
4. Barker AF. Bronchiectasis. N Engl J Med 2002;346:1383-1393.
5. Currie DC, Pavia D, Agnew JE, Lopez-Vidriero MT, Diamond PD, Cole PJ, Clarke SW. Impaired tracheobronchial clearance in bronchiectasis. Thorax 1987;42:126-130. (Pubitemid 17020314)
6. Angrill J, Agusti C, De Celis R, Filella X, Rano A, Elena M, De La Bellacasa JP, Xaubet A, Torres A. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001;164:1628-1632. (Pubitemid 33124150)
7. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-295.
8. Cole PJ. Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15. (Pubitemid 16017382)
9. Lin HC, Cheng HF, Wang CH, Liu CY, Yu CT, Kuo HP. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997;155:2024-2029.
10. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, Vallano A. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999;93:476-480. (Pubitemid 29364062)
11. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.AmJ Respir Crit Care Med 2000;162:481-485.
12. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39:39-44. (Pubitemid 40052376)
13. Murray MP, Doherty CJ, Greening AP, Gray RD, Simpson AJ, Haslett C, Wilkinson TS, Chalmers JD, Hill AT. Long term nebulised gentamicin in non-cystic fibrosis bronchiectasis improves microbial load, exercise tolerance, exacerbation frequency and health related quality of life. British Thoracic Society Winter Meeting December 2009. London, UK. Thorax 2009;64:A103.
14. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003;58:339-343. (Pubitemid 36411421)
15. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145: 1321-1327.
16. Naidich DP, McCauley DI, Khouri NF, Stitik FP, Siegelman SS. Computed tomography of bronchiectasis. J Comput Assist Tomogr 1982;6:437-444. (Pubitemid 12123025)
17. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. Ct findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995;165:261-267.
18. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946. (Pubitemid 38807371)
19. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204. (Pubitemid 17009877)
20. Murray MP, Pentland JL, Turnbull K, MacQuarrie S, Hill AT. Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34:361-364.
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-338. (Pubitemid 41079078)
22. Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999;54:213-222. (Pubitemid 29110500)
23. Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009;34:125-131.
24. Raj AA, Pavord DI, Birring SS. Clinical cough. IV: What is the minimal important difference for the Leicester Cough Questionnaire? Handb Exp Pharmacol 2009;187:311-320.
25. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156:536-541. (Pubitemid 27351991)
26. Murray MP, Doherty CJ, Govan JR, Hill AT. Do timing and storage of sputum influence quantitative bacteriology in bronchiectasis? J Med Microbiol 2010;59:829-833.
27. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests, ninth edition, and performance standards for antimicrobial susceptibilty testing, sixteenth informational supplement; M02-A9 and M100-S16 package. Wayne, PA: CLSI; 2006.
28. Steinman RM, Cohn ZA. The interaction of soluble horseradish peroxidase with mouse peritoneal macrophages in vitro. J Cell Biol 1972;55:186-204.
29. Buttle DJ, Burnett D, Abrahamson M. Levels of neutrophil elastase and cathepsin b activities, and cystatins in human sputum: relationship to inflammation. Scand J Clin Lab Invest 1990;50:509-516. (Pubitemid 20255432)
30. Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998;26:31-39. (Pubitemid 28028437)
31. Crowther Labiris NR, Holbrook AM, Chrystyn H, Macleod SM, Newhouse MT. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am J Respir Crit Care Med 1999;160:1711-1716.
32. Twiss J, Byrnes C, Johnson R, Holland D. Nebulised gentamicin-suitable for childhood bronchiectasis. Int J Pharm 2005;295:113-119.
33. Currie DC. Nebulisers for bronchiectasis. Thorax 1997;52:S72-S74. (Pubitemid 27239459)
34. Angrill J, Agusti C, de Celis R, Rano A, Gonzalez J, Sole T, Xaubet A, Rodriguez-Roisin R, Torres A. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57:15-19. (Pubitemid 34081538)
35. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007;101:1633-1638. (Pubitemid 46930715)
36. Couch LA. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001;120:114S-117S.
37. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127:1420-1426. (Pubitemid 46224309)
38. Gillham MI, Sundaram S, Laughton CR, Haworth CS, Bilton D, Foweraker JE. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. J Antimicrob Chemother 2009;63:728-732.
39. Stockley RA, Bayley D, Hill SL, Hill AT, Crooks S, Campbell EJ. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax 2001;56:366-372. (Pubitemid 32398127)
40. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34:1086-1092.
41. Murray MP, Turnbull K, Macquarrie S, Hill AT. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33:312-318.
42. Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, Tipoe GL, Ko C, Yan C, Lam WK, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005;60:239-243. (Pubitemid 40380285)
43. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003;14:488-492. (Pubitemid 38210174)